AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04485052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI188
Description: anti-CD47 Monoclonal antibody
Study NCT04485052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Demethylation drugs
Study NCT04485052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Demethylation drugs
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Vinorelbine tartrate
Description: Vinorelbine tartrate injection
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Carboplatin
Description: Carboplatin injection
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Methotrexate
Description: Methotrexate injection
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Eribulin mesylate
Description: Eribulin mesylate injection
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Toremifene citrate
Description: Toremifene citrate tablets
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Anastrozole
Description: Anastrozole tablets
Study NCT04069247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CBT-I
Description: The e-CBT-I will be delivered through a mobile application (eSleep) with a personal password.
Study NCT04069247 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-HE
Description: The e-HE will be delivered in control though a mobile application (eSleep) with a personal password.
Study NCT00382408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DR-5001
Description: All randomized subjects received a single tablet of both Type-4 and Type-7 ADV vaccines on Day 0. Both vaccine tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Letrozole
Description: Letrozole tablets
Study NCT00382408 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All randomized subjects received a single tablet each of the placebos matching Type-4 and Type-7 ADV vaccines on Day 0. Both placebo tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Exemestane
Description: Exemestane tablets
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Fulvestrant
Description: Fulvestrant injection
Study NCT01996397 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardiac resynchronization therapy device implantation
Study NCT01792583 — intervention group
Intervention type: DRUG
Intervention: Modafinil/armodafinil
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Olaparib
Description: Olapani pill
Study NCT01347281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of [18F]HX4
Description: Injection of \[18F\]HX4 before treatment (baseline) and after radiotherapy with 20 +/-4 Gy:~\[18F\]HX4 PET scans; 444 MBq (12 mCi) \[18F\]HX4 administrated via a bolus IV injection. Image acquisition: static scan at 240 min p.i.~Venous blood sampling: before injection of \[18F\]HX4 (blood hypoxia markers) Follow-up (3 months after treatment): \[18F\]FDG PET in treatment position
Study NCT00616486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: 6 weeks of stimulation with RMT frequency 1Hz, intensity 110% of RMT for 20 minutes, 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
Study NCT00616486 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham (placebo)
Description: Sham treatment will mimic active treatment mentioned above.
Study NCT02206464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Shanghai/02/2013 (H7N9) MIV
Description: Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab injection
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Apatinib mesylate
Description: Apatinib mesylate tablets
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Pattozumab
Description: Pattozumab injection
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine tablets
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Ear particles
Description: Ear particles
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Aidi Injection
Description: Aidi Injection
Study NCT03925233 — intervention group
Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Cyclophosphamide injection
Study NCT01187771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Gastric Banding
Description: Those randomized to surgery would meet with the bariatric surgeon and the dietitian during the 3 month weight management period and based on insurance requirements, would undergo LGB surgery after 3 months of weight management. PAP therapy would be utilized for the 3 week peri-operative period (1 week prior to 2 weeks post-operatively) given evidence that this might reduce peri-operative respiratory complications. Routine surgical follow-up will occur 2 weeks post-operatively and then every 4-6 weeks to assess weight loss trajectory and adjust the band as needed.
Study NCT01187771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: Participants randomized to the CPAP arm will undergo a CPAP titration within 2 weeks of enrollment unless a split-night study was already performed as part of their diagnostic polysomnogram (PSG) providing a reliable CPAP therapeutic pressure. As soon as an appropriate pressure is identified, CPAP therapy will begin with routinely scheduled follow-up visits to maximize CPAP adherence. All participants will be offered a 12 month supervised weight loss program in addition to OSA-specific therapy.
Study NCT03999827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Glycaemic Index Diet
Description: Adherence to a diet which limits carbohydrate intake to 40-60 g/day, but carbohydrates must have a glycaemic index of less than 50. Fat and protein intake is encouraged, with approximately 60% of calorie intake as fat.
Study NCT03999827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycaemic Index Diet
Description: Adherence to a diet which limits carbohydrate intake to 40-60 g/day, but carbohydrates must have a glycaemic index of less than 50. Fat and protein intake is encouraged, with approximately 60% of calorie intake as fat.
Study NCT03036865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS161721
Description: Single dose administered IV or SC
Study NCT03036865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose administered IV or SC
Study NCT03994042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mental imagery neurofeedback training
Description: Mental Imagery (MI)-neurofeedback training, 2-3 hours, 3 times/week for 4 weeks.
Study NCT00744094 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein drink
Description: 250 ml protein hydrolysate solution
Study NCT00744094 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training
Description: 12 weeks resistance training, 3 days per week
Study NCT00744094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 12 weeks resistance training, 3 days per week
Study NCT03688152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914
Description: Dose Escalation: INCB053914 at the protocol-defined starting dose in combination with INCB050465, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study.
Study NCT03688152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB050465
Description: Dose Escalation: INCB050465 at the protocol-defined starting dose in combination with INCB053914, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study.
Study NCT05265663 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic ablative radiotherapy
Description: SABR will be delivered in an image-guided hypofractionated scheme of 5 fractions of 8 Gy (total 40 Gy), prescribed to 95% of the planning target volume (PTV). Treatment is delivered on alternate days within a maximum overall treatment duration of 14 days.
Study NCT01471132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 345mg/m2,43℃，30mins
Study NCT01471132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 260mg/m2,43℃，30mins
Study NCT03950180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prostate Cancer Comorbidity Index (PCCI) score
Description: Life expectancy information
Study NCT03381001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embryo transfer after thaw and culture
Description: embryos will be kept in culture after thawing for one day before transfer for the uterus
Study NCT03381001 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: embryo transfer with no culture
Description: embryos will be transfer with no culture after thaw
Study NCT03712735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.08% - fentanyl 2mcg
Description: In each arm, bupivacaine and fentanyl are being delivered at different intervals and rates for the maintenance of labor analgesia.
Study NCT03712735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.08% - fentanyl 2mcg
Description: In each arm, bupivacaine and fentanyl are being delivered at different intervals and rates for the maintenance of labor analgesia.
Study NCT01782742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexarotene
Description: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo
Study NCT01782742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01953003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinflunine
Description: intravenous administration day 1 once every 3 weeks, 280 mg/m²
Study NCT01953003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Arm A : 1650 mg/m² Arm B : 2500 mg/m²
Study NCT01953003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Arm A : 1650 mg/m² Arm B : 2500 mg/m²
Study NCT04495439 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Augmentation with the ISS Study System
Description: Augmentation with the ISS Study System
Study NCT04495439 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Augmentation with PMMA
Description: Augmentation with PMMA (standard)
Study NCT01043016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: patient undergo Photocyanine Injection via venous infusion followed by photodynamic therapy with 670nm diobe laser 24 hours later
Study NCT02512679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide Dose Level 1
Description: given by IV at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level. After ten patients the de-escalation will begin if the stopping rule is not met.
Study NCT02512679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide Dose Level 2
Description: Level 2 will be 70mg/kg in 2 divided given once a day for 2 days;
Study NCT02512679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide Dose Level 3
Description: Level 3 will be 35mg/kg as a one-time dose.
Study NCT02512679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide Dose Level 4
Description: Level 4 will be no cytoxan.
Study NCT02098408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Description: Neurocognition will be trained using the NEAR model (Medalia et al. 2003), whereas the training of social cognitive skills will be by use of the SCIT manual (Social Cognition and Interaction Training) developed by Roberts et al. 2014.~The intervention consists of 24 group sessions taking place once a week (two hours) and additional neurocognitive training at home. Furthermore, there will be a total of 12 individual sessions aiming at bridging the cognitive training to the everyday functioning of the patients.
Study NCT02098408 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling.
Study NCT02098408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling.
Study NCT04959630 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinical decision making based on visualizing liver 3D models in Virtual Reality (VR) environment or via a Desktop Interface (DI)
Description: Visualizing 3D models of livers for preoperative surgical planning via two different environment: DI and VR in sequential order
Study NCT02675478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Study NCT01255592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: Oral dose bid
Study NCT03489707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based human papillomavirus (HPV) DNA screening
Description: Persons randomized to arm 1 will receive an HPV DNA home-based collection kit in the mail at 0 and 12 months.
Study NCT03489707 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic-based human papillomavirus (HPV) DNA screening
Description: Persons randomized to arm 2 will attend a clinic where a clinician will collect the DNA specimen at 0 and 12 months.
Study NCT01255592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose bid
Study NCT02025114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
Study NCT03830645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Application of platelet rich plasma through the intercostal tube into the pleural space
Study NCT00830674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose IV or SC administration
Study NCT00830674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN23
Description: Single IV administration on day 1: 0.003, 0.01, 0.03, 0.1 and 0.3 mg/kg and Single SC administration on day 1: 0.1, 0.3, 0.6 and 1.0 mg/kg
Study NCT00329602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT00329602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropinirole
Description: Ropinirole IR 0.25mg/day to 4mg/day for RLS
Study NCT00329602 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ropinirole
Description: Ropinirole IR 0.25mg/day to 4mg/day for RLS
Study NCT02133755 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bromocriptine
Description: Three month administration of bromocriptine. Baseline ultrasound and laboratory parameters measured. Repeat measures at discontinuation of drug at 3 months.
Study NCT03253289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meclizine Oral Tablet
Description: All subjects will receive 50 mg of meclizine taken orally, twice a day (daily dose 100 mg) for 28 (up to 35) days.
Study NCT00581321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water
Description: water 500 ml x 1
Study NCT03439189 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Methacetin Breath Test
Description: A breath analyzer will be used to measure changes in carbon-12 to carbon-13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.
Study NCT03439189 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Methacetin Breath Test
Description: A breath analyzer will be used to measure changes in carbon-12 to carbon-13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.
Study NCT03439189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emricasan
Description: Investigational drug for NASH treatment in Main Conatus protocol
Study NCT03439189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo versus emricasan in Conatus NASH treatment trial
Study NCT01042509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab and rituximab
Description: Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25
Study NCT01388348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Urine Vibration Holter
Description: each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study
Study NCT00336843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin-BuCyE
Description: rituximab (IV, 250 mg/m2 on days -21 and -14) single dose of 90Y-ibritumomab (IV, 0.4 mCi/kg on day -14) Busulfan (IV, 0.8 mg/kg every 6 h from day -7 to day -5) Cyclophosphamide (IV, 50 mg/kg on days -3 and -2) Etoposide (IV, 200 mg/m2 every 12 h on days -5 and -4) Autologous stem cells infusion on day 0
Study NCT01921881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: St John's wort
Study NCT03319511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal group
Description: plain bupivacaine 0.5%,1.5 ml plus dexmedetomidine 5 μg. once injection.
Study NCT03319511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral group
Description: plain bupivacaine 0.5%, 0.3 ml (1.5 mg)/kg plus dexmedetomidine 0.5 μg /kg divided between the T2 and T4 levels.
Study NCT03010839 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Remote Ischemic Preconditioning
Description: mRIPC will be induced at 24 h, 12 h and 1 h before surgery and once before induction of anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
Study NCT03010839 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control group witnout remote ischemic preconditioning
Study NCT00998907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDS plus
Description: triclosan-coated polydiaxanon 910 suture materials with antiseptic activity (PDS plus®, Ethicon GmbH, Norderstedt, Germany)
Study NCT00998907 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PDS II
Description: polyglactin 910 suture material for abdominal wall closure
Study NCT03844022 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: magnetic resonance imaging
Study NCT00682032 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-glucan
Description: AIM 2: regimen to begin after baseline blood draw; AIM 3: regimen to begin after baseline blood draw and to be completed prior to surgery
Study NCT00959959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOK-001
Description: 2 capsules (325 mg each), once per day
Study NCT00959959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOK-001
Description: 4 capsules (325 mg each), once per day
Study NCT00959959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOK-001
Description: 6 capsules (325 mg each), once per day
Study NCT00959959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOK-001
Description: 3 capsules (325 mg each), once per day
Study NCT00959959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOK-001
Description: 3 capsules (325 mg each), once per day with supplement
Study NCT00959959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOK-001
Description: 6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
Study NCT00959959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOK-001
Description: 8 capsules (325 mg each), once per day
Study NCT03794076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cromoglycate
Description: Cromoglycate will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray